Novel Interventions for Adults with Obsessive-Compulsive Disorder

描述（由申请人提供）：强迫症（OCD）是导致疾病相关残疾的主要原因。迫切需要更有效的治疗方法，副作用更少，起效更快。认知行为疗法非常有效，但不容易传播，许多患者难以执行。5-羟色胺再摄取抑制剂（SRI）在某些患者中仅中度有效，并且在症状减轻之前有很长的滞后时间（610周）。SRI通常也会导致性功能障碍，这是患者停药的主要原因。唯一被证明可以增加SRI的药物是添加抗精神病药物，这对三分之一的患者有帮助;然而，体重增加和镇静的副作用也会导致高停药率。我的目标是整合最新的基础科学和疾病的病理生理学，并利用这些知识来识别和测试针对强迫症和相关疾病的潜在神经生物学机制的新药。我在这个指导以患者为导向的研究职业发展奖（K23）的重点是谷氨酸系统，因为最近的人类和动物数据涉及在强迫症的皮质纹状体回路异常的谷氨酸能功能。此外，被认为调节谷氨酸系统的药物在开放标签试验中显示出希望。职业发展计划将侧重于发展：1）在强迫症的现象学和神经生物学的专业知识，以确定新的治疗目标; 2）在临床试验的设计，执行和分析技能，以测试新的化合物; 3）深入了解磁共振波谱（MRS）方法，以测试治疗对大脑的影响。研究计划将测试强迫症中两种假定的谷氨酸调节剂：项目#1是米诺环素的随机试验，认为米诺环素通过神经胶质机制起作用，以增加强迫症患者的SRI。初步数据表明，它是耐受性良好，并可能有显着的症状减轻一些患者。米诺环素的优点是成本低，FDA批准用于儿童e12（用于长期治疗痤疮），并且比抗精神病药物副作用少。我们的目标是检查米诺环素作为SRI的辅助药物的效果，以确定米诺环素是否值得在R 01中应用。项目#2：是一项在既往SRI试验失败的无药物强迫症患者中进行的氯胺酮（一种谷氨酸受体拮抗剂）随机试验。目的是确定氯胺酮在强迫症中的安全性和可行性，并探索氯胺酮对强迫症症状和前扣带皮层谷氨酸测量的影响。这些项目将有助于研究神经元系统在强迫症中的作用，并探索强迫症的新治疗方法;来自任何一个项目的有希望的数据将导致未来的R 01研究。在这个过程中，我将获得必要的技能和经验，以启动我的职业生涯作为一个独立的，以病人为导向的研究人员。这项研究通过测试新的强迫症干预措施（策略3.1）和探索治疗反应的潜在标志物（策略1.3）来促进NIMH战略计划。

DESCRIPTION (provided by applicant): Obsessive compulsive disorder (OCD) is a leading cause of illness related disability. More effective treatments with fewer side effects and faster onset of action are desperately needed. Cognitive behavioral therapy is highly effective, but not easily disseminated and difficult for many patients to execute. Serotonin reuptake inhibitors (SRIs) are only moderately effective in some patients and have a long lag time (610 weeks) before symptom reduction. SRIs also commonly cause sexual dysfunction, a major reason for patient discontinuation. The only medications proven to augment SRIs is the addition of antipsychotics, which help up to a third of patients; however, the side effects of weight gain and sedation also lead to high rates of discontinuation. My goal is to integrate the latest basic science and pathophysiology of disease and to use that knowledge to identify and test new drugs directed at underlying neurobiological mechanisms of OCD and related disorders. My focus during this Mentored PatientOriented Research Career Development Award (K23) is the glutamate system because recent human and animal data implicate abnormal glutamatergic functioning in cortico-striatial circuits in OCD. Moreover, medications thought to modulate the glutamate system have shown promise in open label trials. The Career Development Plan will focus on developing: 1) expertise in the phenomenology and neurobiology of OCD to identify novel treatment targets; 2) skill in the design, conduct, and analysis of clinical trials to test novel compounds; 3) in-depth knowledge of magnetic resonance spectroscopy (MRS) methods to test the effects of treatments on the brain. The Research Plan will test two putative glutamate modulators in OCD: Project #1 is a randomized trial of minocycline, thought to act through glial mechanisms, to augment SRIs in OCD patients. Pilot data suggest that it is well tolerated and may have dramatic symptom reduction in some patients. Advantages of minocycline are low cost, FDA approval in children e12 (for long-term treatment of acne), and less side effects than antipsychotics. The goal is to examine the effects of minocycline as an adjunct to SRIs to determine if minocycline is worth pursuing in an R01 application. Project #2: is a randomized trial of ketamine, a glutamate receptor antagonist, in drug free OCD patients who have failed prior SRI trials. The goal is to determine safety and feasibility of ketamine in OCD and to explore ketamine effects on OCD symptoms and on glutamate measures in the anterior cingulate cortex. Together these projects will help examine the role of the glutamatergic system in OCD and explore novel treatments for OCD; promising data from either project will lead to future R01 studies. In the process, I will acquire skills and experience necessary to launch my career as an independent, patient oriented researcher. This study promotes the NIMH strategic plan by testing novel interventions for OCD (Strategy 3.1) and exploring a potential marker of treatment response (Strategy 1.3).